Stock market announcement archive

LIFE – Successfully completed four weeks of longevity trials

July 17, 2024
Bergen, Norway, 17 July 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce positive results from the first four week of sensor longevity trials. Reference is made to press releases 18 June 2024 when the company initiated the trials with wireless readout. The […]
Read more

LIFE: Cleanroom arrived in Hamburg

July 2, 2024
Bergen, Norway, July 2, 2024: Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the cleanroom for automated production has arrived in Hamburg. Reference is made to Lifecare’s stock exchange announcement March 5, 2024, regarding placing a purchase order for cleanroom in connection with the […]
Read more

LIFE: Successfully completed first week of longevity trials

June 27, 2024
Bergen, Norway, 27 June 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can announce positive results from the first week of sensor longevity trials. Reference is made to press release 18 June 2024 when the company initiated the trials with wireless readout. Already after […]
Read more

LIFE – Longevity trials in dogs starts today

June 18, 2024
Bergen, Norway, 18 June 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company will starts the longevity trials in dogs today. Reference is made to stock exchange notification June 10th and June 13th, 2024. The company have improved the read-out distance […]
Read more

LIFE: Satisfied with the final results of the Rights Issue

June 14, 2024
Bergen, Norway, 14 June, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that all valid subscriptions from investors with subscription rights have been allocated in accordance with the allocation criteria set out in the prospectus for the Rights Issue. Reference is made to […]
Read more

LIFE – Improved read out distance for sensor – preparing for longevity trials in dogs

June 10, 2024
Bergen, Norway, June 10th, 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the company have improved the read-out distance from sensor to the read-out device. Reference is made to previous communications in the Q1 reporting regarding the need to improve the read-out […]
Read more

Minutes from Annual General Meeting

April 30, 2024
The Annual General Meeting of Lifecare AS was convened as a hybrid meeting on 30 April 2024. Trine Teigland (Board member) and Lutz Heinemann (Board member) were re-elected and Tone Kvåle (Board member) was elected as new member of the BoD as proposed by the Nomination Committee. No alternative candidates were proposed. All proposals on […]
Read more

LIFE – Lifecare becomes majority shareholder in RemovAid

April 29, 2024
Bergen, Norway, 29 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), have invested NOK 2 million through a private placement in RemovAid AS, a medical technology company based in Oslo, Norway, after which Lifecare holds 81.1% of the shares in RemovAid. RemovAid has developed […]
Read more

LIFE – Strategic investment in RemovAid AS

April 26, 2024
Bergen, Norway, 26th April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intend to invest NOK 2 million and become the majority shareholder in RemovAid AS, a medical technology company based in Oslo, Norway. RemovAid is an ISO 13485 certified company who specializes in the […]
Read more

LIFE: Lifecare BoD propose a partially underwritten rights issue

April 26, 2024
Bergen, Norway, 26 April 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), intent to invite its existing shareholders in a NOK 90 million partially underwritten rights issue. The proposed rights issue will ensure preferential subscription rights for existing shareholders, with already underwritten guarantees a minimum […]
Read more